medigraphic.com
Instituto Nacional de Salud Pública

2025, Number 6

<< Back Next >>

salud publica mex 2025; 67 (6)

Hypertension in adults and gaps in care at the national and state levels, Ensanut 2021-2024

Campos-Nonato I, Monterrubio-Flores E, Ramírez-Villalobos D, Arias-Mendoza MA, Gómez-Álvarez E, Alcocer-Díaz-Barreiro L, Basto-Abreu A, Reyes-García A, Medina-García C, Hernández-Barrera L, Barquera S

Language: Spanish
References: 31
Page: 633-643
PDF size: 393.20 Kb.


ABSTRACT

Objective. To describe the prevalence of adults with diagnosed, treated, and controlled hypertension, disaggregated at the national and state levels, and to estimate the number of people who may develop cardiovascular disease (CVD) due to hypertension. Materials and methods. Data from 34 954 participants in the Encuesta Nacional de Salud y Nutrición 2021-2024 survey were analyzed. Prevalence rates were estimated at the national and state levels. Using the Globorisk and the WHO risk score, the number of people who could develop CVD due to hypertension was estimated. Results. Nationally, the prevalence of hypertension in adults was 29.1%. The 62.9% of adults with hypertension were aware of their condition, and 60.1% of those treated with medication had blood pressure (BP) under control. The lowest prevalence of hypertension was observed in Colima (21.3%) and the highest in Sonora (40.7%). 1 119 060 CVD events could be avoided over the next 10 years if BP in adults were normalized. Conclusions. Hypertension is a public health problem in Mexico, and the health system’s performance in controlling adult BP is lower in the northern states. Prompt, coordinated, population-based strategies are needed to reduce the burden of hypertension in Mexico.


REFERENCES

  1. Organización Mundial de la Salud, Organización Panamericana de laSalud. Hipertension. Washington DC: OMS/OPS, 2025 [citado septiembre 29, 2025]. Disponible en: https://www.paho.org/es/enlace/hipertension

  2. Levy PD, Cline D. Asymptomatic hypertension in the emergency department:a matter of critical public health importance. Acad Emerg Med.2009;16(11):1251-7. https://doi.org/10.1111/j.1553-2712.2009.00512.x

  3. Bidani AK, Griffin KA. Basic science: hypertensive target organdamage. J Am Soc Hypertens. 2015;9(3):235-7. https://doi.org/10.1016/j.jash.2015.01.005

  4. Bautista-Arredondo S, Vargas-Flores A, Moreno-Aguilar LA, ColcheroMA. Utilización de servicios de salud en México: cascada de atenciónprimaria en 2022. Salud Publica Mex. 2023;65(supl 1):s15-22. https://doi.org/10.21149/14813

  5. Organización Mundial de la Salud, Organización Panamericana de la Salud.Compendium of indicators for monitoring regional and global noncommunicabledisease response in the Americas. Washington DC: OMS/OPS, 2015[citado septiembre 29, 2025]. Disponible en: https://www3.paho.org/hq/dmdocuments/2015/NCD-Compendium-of-indicators-2015.pdf

  6. Global report on hypertension: the race against a silent killer. Ginebra:World Health Organization, 2023 [citado en septiembre 29, 2025]. Disponibleen: https://www.who.int/publications/i/item/9789240081062

  7. Campos-Nonato I, Oviedo-Solís C, Hernández-Barrera L, Márquez-Murillo M, Gómez-Álvarez E, Alcocer L, et al. Detección, atención ycontrol de hipertensión arterial. Salud Publica Mex. 2024;66(4):539-48.https://doi.org/10.21149/15867

  8. Campos-Nonato I, Oviedo-Solís C, Vargas-Meza J, Ramírez-Villalobos D,Medina-García C, Gómez-Álvarez E, et al. Prevalence, treatment and controlof hypertension in Mexican adults: results of the Ensanut 2022. SaludPublica Mex. 2023;65(supl 1):s169-80. https://doi.org/10.21149/14779

  9. Peters MA, Noonan CM, Rao KD, Anbrasi E, Olakunle OA. Evidencefor an expanded hypertension care cascade in low- and middle-incomecountries: a scoping review. BMC Health Serv Res. 2022;22:827. https://doi.org/10.1186/s12913-022-08190-0

  10. Romero-Martínez M, Shamah-Levy T, Barrientos-Gutiérrez T, Cuevas-Nasu L, Bautista-Arredondo S, Colchero MA, et al. Metodología y análisisde la Encuesta Nacional de Salud y Nutrición Continua 2020-2024. SaludPublica Mex. 2024;66(6):879-85. https://doi.org/10.21149/16455

  11. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al.Recommendations for blood pressure measurement in humans andexperimental animals: Part 1: blood pressure measurement in humans: astatement for professionals from the Subcommittee of Professional andPublic Education of the American Heart Association Council on HighBlood Pressure Research. Hypertension. 2005;45(1):142-61. https://doi.org/10.1161/01.HYP.0000150859.47929.8e

  12. Williams B, Mancia G, Spiering W, Agabiti-Rosei E, Azizi M, Burnier M, etal. 2018 ESC/ESH Guidelines for the management of arterial hypertension:The Task Force for the management of arterial hypertension of the EuropeanSociety of Cardiology (ESC) and the European Society of Hypertension(ESH). Eur Heart J. 2018;39(33):3021-104. https://doi.org/10.1093/eurheartj/ehy339

  13. Lohman T, Roche A, Martorell R. Anthropometric standarization referencemanual. Champaign, Illinois: Human Kinetics, 1988:184.

  14. Organización Mundial de la Salud. Physical status: the use of andinterpretation of anthropometry, report of a WHO expert committee.Ginebra: OMS, 1995 [citado septiembre 29, 2025]. Disponible en: https://apps.who.int/iris/handle/10665/37003

  15. Ueda P, Woodward M, Lu Y, Hajifathalian K, Al-Wotayan R, Aguilar-SalinasCA, et al. Laboratory-based and office-based risk scores and charts to predict10-year risk of cardiovascular disease in 182 countries: a pooled analysisof prospective cohorts and health surveys. Lancet Diabetes Endocrinol.2017;5(3):196-213. https://doi.org/10.1016/S2213-8587(17)30015-3

  16. Kaptoge S, Pennells L, Bacquer DD, Cooney MT, Kavousi M, StevensG, et al. World Health Organization cardiovascular disease risk charts:revised models to estimate risk in 21 global regions. Lancet Glob Health.2019;7(10):e1332-45. https://doi.org/10.1016/S2214-109X(19)30318-3

  17. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ,Stevens GA, et al. Worldwide trends in hypertension prevalenceand progress in treatment and control from 1990 to 2019: a pooledanalysis of 1201 population-representative studies with 104 millionparticipants. Lancet. 2021;398(10304):957-80. https://doi.org/10.1016/S0140-6736(21)01330-1

  18. Edwards EW, Saari HD, DiPette DJ. Inadequate hypertension controlrates: a global concern for countries of all income levels. J Clin Hypertens(Greenwich). 2022;24(3):362-4. https://doi.org/10.1111/jch.14444

  19. Casey MM, Thiede Call K, Klingner JM. Are rural residents less likelyto obtain recommended preventive healthcare services? Am J Prev Med. 2001;21(3):182-8. https://doi.org/10.1016/s0749-3797(01)00349-x

  20. Consejo Nacional de Evaluación de la Política de Desarrollo Social.Informe de la pobreza multidimensional en México, 2020. Metodología actualizada2018-2020. Ciudad de México: Coneval, 2022 [citado septiembre29, 2025]. Disponible en: https://www.coneval.org.mx/InformesPublicaciones/Paginas/Mosaicos/Informe_de_pobreza_2020.aspx

  21. Strickland W, Strickland D. Barriers to preventive health services forminority households in the rural south. J Rural Health. 1996;12:206-17.

  22. Blok S, Haggenburg S, Collard D, Van Der Linden E, GalenkampH, Moll van C, et al. The association between socioeconomic statusand prevalence, awareness, treatment and control of hypertensionin different ethnic groups: the Healthy Life in an Urban Settingstudy. J Hypertens. 2022;40(5):897-907. https://doi.org/10.1097/HJH.0000000000003092

  23. Leng B, Jin Y, Li G, Chen L, Jin N. Socioeconomic status and hypertension:a meta-analysis. J Hypertens. 2015;33(2):221-9. https://doi.org/10.1097/HJH.0000000000000428

  24. Zajacova A, Lawrence EM. The relationship between education andhealth: Reducing disparities through a contextual approach. Annu RevPublic Health. 2028;39(1):273-89. https://doi.org/10.1146/annurev-publhealth-031816-044628

  25. Wozniak G, Khan T, Gillespie C, Sifuentes L, Hasan O, Ritchey M, etal. Hypertension control cascade: a framework to improve hypertensionawareness, treatment, and control. J Clin Hypertens. 2016;18(3):232-9.https://doi.org/10.1111/jch.12654

  26. Colchero MA, Gómez R, Bautista-Arredondo S. Caracterización dela “cascada de atención” en servicios públicos en México en localidadesde menos de 100 000 habitantes. Salud Publica Mex. 2019;61(6):734-41.https://doi.org/10.21149/10570

  27. Koeppel L, Dittrich S, Brenner-Miguel S, Carmona S, Ongarello S,Vetter B, et al. Addressing the diagnostic gap in hypertension throughpossible interventions and scale-up: a microsimulation study. PLoS Med.2022;19(12):e1004111. https://doi.org/10.1371/journal.pmed.1004111

  28. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, PrabhakaranD, et al. 2020 International Society of Hypertension Global HypertensionPractice guidelines. Hypertension. 2020;75:1334-57. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026

  29. Chaturvedi A, Zhu A, Gadela NV, Prabhakaran D, Jafar TH. Socialdeterminants of health and disparities in hypertension and cardiovasculardiseases. Hypertension. 2024;81(3):387-99. https://doi.org/10.1161/HYPERTENSIONAHA.123.21354

  30. Organización Mundial de la Salud. Adherencia a los tratamientos alargo plazo: pruebas para la acción. Red Mundial Interdisciplinaria sobreAdherencia Terapéutica. Ginebra: OMS, 2004 [citado septiembre 29, 2025].Disponible en: https://www3.paho.org/hq/dmdocuments/2012/WHOAdherence-Long-Term-Therapies-Spa-2003.pdf

  31. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specificrelevance of usual blood pressure to vascular mortality: a metaanalysisof individual data for one million adults in 61 prospective studies.Lancet. 2002;360(9349):1903-13. https://doi.org/10.1016/s0140-6736(02)11911-8




2020     |     www.medigraphic.com